TriSalus Life Sciences director Gordon buys 10,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
TriSalus Life Sciences, Inc. (TLSI) director Gary B. Gordon purchased 10,000 common shares at $2.20 per share on November 17, 2026. The purchase was reported as direct ownership, bringing his reported holdings to 82,510 shares. No Rule 10b5-1 plan is reported.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
1 txn
Insider
Gordon Gary B.
Role
Director
Bought
10,000 shs ($22K)
Increase in Position
13.8%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 10,000 | $2.20 | $22K |
Holdings After Transaction:
Common Stock — 82,510 shares (Direct)
Holdings Before and After:
Common Stock, 72,510 to 82,510 shares (Direct)
Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Key Figures
Shares purchased: 10,000 shares
Purchase price: $2.20 per share
Shares held after purchase: 82,510 shares
3 metrics
Shares purchased
10,000 shares
Gary B. Gordon's direct purchase on November 17, 2026
Purchase price
$2.20 per share
Gary B. Gordon's purchase on November 17, 2026
Shares held after purchase
82,510 shares
Gary B. Gordon's reported direct holdings following the transaction
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.